Almac Group Limited Company Profile
Integrated Solutions from Research to Commercialisation.
Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.
Our vast range of services include:
Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory.
API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.
Pharmaceutical Development: Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.
Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.
Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.
Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.
Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.
Almac – Partnering to Advance Human Health™
20 Seagoe Industrial Estate
Phone: +44 (0) 28 3833 2200
Almac has doubled its API stability storage with the completion of a $2m (€1.6m) investment in both the UK and US.
Linking peptide and small molecule drugs to albumin will improve pharmacokinetics, says Almac as it partners its manufacturing capabilities with Novozymes’ half-life extension platform.
Genomic Health, Inc and Almac Group have established an agreement in which Genomic Health will exclusively license Almac’s technology and intellectual property to further develop, validate and comme...
Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize...
Almac introduces a new [14C]-labelled antibody drug conjugate service to support the development of targeted drug treatments.
Almac says it is in a unique position to offer Carbon-14 ADME studies for the growing antibody-drug conjugate (ADC) market and has already performed the service on a Pfizer candidate.
Genomic Health Inc. licensed rights to fellow cancer testing company Almac Diagnostics’ technology and IP related to the further development of a genomics-based product that will predict the likelih...
Q: What have Profil Institute, Almac, Celerion and PDI all have in common? A: They all made it in this week's Outsourcing-Pharma People on the Move.
Drugs and Medications
The physiological and biochemical characteristics of isolates from swine in Sweden and The Netherlands were compared with those of strains from several culture collections. These characteristics were...
Guidelines for the best steroid dose in children with tuberculous meningitis (TBM) have not been established. We enrolled 63 children with TBM and divided them into three steroid dose groups: Group 1...
Abstract Purpose: To evaluate the tear-film meniscus with optical coherence tomography (OCT) in patients with Graves' disease (GD). Materials and methods: Patients with GD without clinical features of...
DNA clones that encode the group-II subunits of soybean glycinin were identified and compared with clones for group-I subunits. The group-I clones hybridize weakly to those from group-II at low string...
OBJECTIVE. The aim of this study was to assess age-related visual functions (visual acuity and contrast sensitivity) and compare the results by different age groups. MATERIAL AND METHODS. A total of 2...
The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...
Assessing OCD before and after group therapy
The purpose of this study is to determine whether cognitive-behavioral group prevention (CBT-G) for german children is effective and to what extent parental group training moderates outcom...
The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the pati...
To compare the clinical efficacy of donepezil between the naive group and the switching group.
Integrated Solutions from Research to Commercialisation. Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies world...
W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital...
PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...
Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...
The Man Group has its origins over 200 years ago in a broking business founded by James Man and was floated on the London Stock Exchange in 1994. Man Group plc trades on the London Stock Exchange (EMG...
More Information about "Almac Group Limited" on BioPortfolio
We have published hundreds of Almac Group Limited news stories on BioPortfolio along with dozens of Almac Group Limited Clinical Trials and PubMed Articles about Almac Group Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Almac Group Limited Companies in our database. You can also find out about relevant Almac Group Limited Drugs and Medications on this site too.